



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 July 2020
EMA/254662/2020
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 22-25 June 2020

During its June 2020 meeting, the CHMP reviewed 2 recommendations for eligibility to PRIME: 2 were denied. In addition, 1 request was received but not started by EMA as it was deemed outside the scope of the scheme.

The individual outcomes adopted this month are listed below.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union





Eligibility denied

Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Radiopharmaceutical	Oncology	Treatment of relapse/refractory multiple myeloma in patients having received four prior treatment regimens or more	Nonclinical+ Clinical exploratory	SME
Biological	Immunology- Rheumatology- Transplantation	Treatment of systemic sclerosis	Nonclinical+ Clinical exploratory	SME

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Cumulative overview of recommendations on PRIME eligibility requests adopted by 25 June 2020



By type of applicant



* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.